Commercial agreement formed for marketing and distribution of Tramal in China

A licence and distribution agreement has been formed between Grünenthal and Mundipharma, which will see Mundipharma market and distribute Tramal (tramadol) in China from the beginning of May.

Tramal, developed by Grünenthal, is an analgesic for moderate to severe pain. It is the only branded form of tramadol that is available in China as sustained-release tablets, immediate release capsules and as an intravenous formulation.

“Poorly controlled post-operative pain may delay the recovery process, and negatively impact patients’ quality of life. With Tramal, which has a long track record in the Chinese market, we are proud to offer a solution that helps patients in need,” explained Gabriel Baertschi, CEO Grünenthal. “Given Mundipharma’s strong commitment and experience in pain management in China, we hope to make Tramal available for even more Chinese pain-patients in need of effective medication.”

“The addition of Tramal to our portfolio reinforces Mundipharma’s position as the international leader in advancing appropriate cancer-related pain relief in China,” said Raman Singh, CEO Mundipharma. “PCIA is an advanced option for medical professionals to treat patients suffering from moderate to severe pain. We are pleased to extend our relationship with Grünenthal to advance the treatment of patients in China, where there remains an unmet patient need. Both organisations are committed to ensuring the responsible use of analgesic medications to treat post-operative patients when other options provide insufficient relief.”